[
  {
    "ts": null,
    "headline": "Alternative Economic Data Point to Solid Growth",
    "summary": "Washington may be closed for business, but the economy keeps humming. Plus, investment newsletter commentary on housing-market troubles, the oil-price outlook, and attractive dividend stocks.",
    "url": "https://finnhub.io/api/news?id=447cac8bc78bd267ced525f7abeca59b96c027dae64a38df149cfc4bcffad7a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761949740,
      "headline": "Alternative Economic Data Point to Solid Growth",
      "id": 137294685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Washington may be closed for business, but the economy keeps humming. Plus, investment newsletter commentary on housing-market troubles, the oil-price outlook, and attractive dividend stocks.",
      "url": "https://finnhub.io/api/news?id=447cac8bc78bd267ced525f7abeca59b96c027dae64a38df149cfc4bcffad7a5"
    }
  },
  {
    "ts": null,
    "headline": "The Craneware Group Hosts 340B Rebate Forum, Confirms No New Vendor Needed for Pilot",
    "summary": "The Craneware Group convened leaders from 25 major U.S. health systems, alongside representatives from Beacon/ESP (Berkeley Research Group) and Apexus, the HRSA 340B Prime Vendor, at its U.S. headquarters this week to align on readiness for the now-approved 340B Rebate Model Pilot Program.",
    "url": "https://finnhub.io/api/news?id=fcf1649587c0acd862a995caa6aff174aeabe308fa4e5b186969bac84c38232c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761933600,
      "headline": "The Craneware Group Hosts 340B Rebate Forum, Confirms No New Vendor Needed for Pilot",
      "id": 137279127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Craneware Group convened leaders from 25 major U.S. health systems, alongside representatives from Beacon/ESP (Berkeley Research Group) and Apexus, the HRSA 340B Prime Vendor, at its U.S. headquarters this week to align on readiness for the now-approved 340B Rebate Model Pilot Program.",
      "url": "https://finnhub.io/api/news?id=fcf1649587c0acd862a995caa6aff174aeabe308fa4e5b186969bac84c38232c"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' quarter; Exxon, Chevron post strong earnings",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=0d374a6f615b03923a5b1906860ea67364e16f6df8733aae70ff5a55b47aac48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761911406,
      "headline": "Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' quarter; Exxon, Chevron post strong earnings",
      "id": 137277110,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=0d374a6f615b03923a5b1906860ea67364e16f6df8733aae70ff5a55b47aac48"
    }
  },
  {
    "ts": null,
    "headline": "Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer",
    "summary": "Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in 2026 Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZ",
    "url": "https://finnhub.io/api/news?id=0940b8a2c9fbb557413145f849fce0459d37ba846f0eee1f67881548d5f777d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761908400,
      "headline": "Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer",
      "id": 137277358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in 2026 Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZ",
      "url": "https://finnhub.io/api/news?id=0940b8a2c9fbb557413145f849fce0459d37ba846f0eee1f67881548d5f777d2"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Margin Expansion Tops Narratives With 19.4% EPS Growth and 25.8% Profit Margin",
    "summary": "Merck (MRK) delivered annual earnings growth of 19.4%, outpacing its own 5-year average growth rate of 13.4%. Profit margins moved higher for the period, standing at 25.8% versus 22% last year, continuing a five-year streak of consistent profit expansion and pointing to persistent earnings quality. With the company currently trading below its estimated fair value and offering a lower Price-to-Earnings ratio than its peers, investors may see value. A strong dividend and history of growth...",
    "url": "https://finnhub.io/api/news?id=76977dd74919285332b0e2cbe88b8e28c12fa17df63e6606e62d980f02bdbdae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761905353,
      "headline": "Merck (MRK) Margin Expansion Tops Narratives With 19.4% EPS Growth and 25.8% Profit Margin",
      "id": 137277359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) delivered annual earnings growth of 19.4%, outpacing its own 5-year average growth rate of 13.4%. Profit margins moved higher for the period, standing at 25.8% versus 22% last year, continuing a five-year streak of consistent profit expansion and pointing to persistent earnings quality. With the company currently trading below its estimated fair value and offering a lower Price-to-Earnings ratio than its peers, investors may see value. A strong dividend and history of growth...",
      "url": "https://finnhub.io/api/news?id=76977dd74919285332b0e2cbe88b8e28c12fa17df63e6606e62d980f02bdbdae"
    }
  }
]